Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: A randomized, placebo-controlled, double-blind study
Objective. To evaluate the effect of a single injection of 500 U of botulinum toxin A (BTX-A; Dysport®) on use of oral rescue medication, bladder compliance, continence and quality of life in a randomized, placebo-controlled, double-blind study in patients with incontinence due to neurogenic detruso...
Gespeichert in:
| Veröffentlicht in: | Scandinavian journal of urology and nephrology 2007-01, Vol.41 (4), p.335-340 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 340 |
|---|---|
| container_issue | 4 |
| container_start_page | 335 |
| container_title | Scandinavian journal of urology and nephrology |
| container_volume | 41 |
| creator | Ehren, Ingrid Volz, Daniela Farrelly, Elisabeth Berglund, Lena Brundin, Lou Hultling, Claes Lafolie, Pierre |
| description | Objective. To evaluate the effect of a single injection of 500 U of botulinum toxin A (BTX-A; Dysport®) on use of oral rescue medication, bladder compliance, continence and quality of life in a randomized, placebo-controlled, double-blind study in patients with incontinence due to neurogenic detrusor overactivity. As this group of patients often have severe symptoms, oral tolterodine was allowed as rescue medication and the amount of tolterodine consumed was our primary endpoint. Material and methods. A total of 31 patients with urinary leakage due to spinal cord injury, myelomeningocele, trauma at birth, multiple sclerosis and myelitis of another cause were randomized to intravesical injections of either 500 U of BTX-A or placebo. Intake of tolterodine and episodes of urinary leakage were registered. Cystometry was performed after 6, 12 and 26 weeks and quality of life was assessed. Results. Patients in the BTX-A group had a significantly lower intake of tolterodine throughout the study compared to those in the placebo group (p=0.003). Cystometric capacity was significantly higher at 6 (p |
| doi_str_mv | 10.1080/00365590601068835 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_00365590601068835</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17763227</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-f3ed8a64fbfbf577a2b1b1c20734480ab2d5fce515661369cc69e2b905f654dd3</originalsourceid><addsrcrecordid>eNp1kD1PwzAQhi0EoqXwA1iQF8aAP2InkVgqVD6kSiwwR45jgyGxi-209N_jqoUOCHk46-55Xp0OgHOMrjAq0TVClDNWIY4w4mVJ2QEYY85wRhBnh2C8mWcJqEbgJIR3hBDhmB-DES4KTgkpxqCfaW2kkGsobAtNvxAyQqdh4-LQGTv0MLovY-EUOgs_B9GZuN7MO6MVTP2FiEbZGODKxDdo1eDdq7JGwlZFPwTnoVsqn0LNMpmn4EiLLqizXZ2Al7vZ8-1DNn-6f7ydzjNJCxIzTVVbCp7rJj1WFII0uMGSoILmeYlEQ1qmpWKYcY4pr6TklSJNhZjmLG9bOgHZNjes1GJo6oU3vfDr2glT71of6adqxkuGeeLxlpfeheCV_jUwqjenrv-cOjkXWyel9ardG7vbJuByB4ggRae9sNKEPZfWzQmmibvZcsZq53uxcr5r6yjWnfM_Ev1_j28zqptg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: A randomized, placebo-controlled, double-blind study</title><source>MEDLINE</source><source>Taylor & Francis:Master (3349 titles)</source><source>Taylor & Francis Medical Library - CRKN</source><creator>Ehren, Ingrid ; Volz, Daniela ; Farrelly, Elisabeth ; Berglund, Lena ; Brundin, Lou ; Hultling, Claes ; Lafolie, Pierre</creator><creatorcontrib>Ehren, Ingrid ; Volz, Daniela ; Farrelly, Elisabeth ; Berglund, Lena ; Brundin, Lou ; Hultling, Claes ; Lafolie, Pierre</creatorcontrib><description>Objective. To evaluate the effect of a single injection of 500 U of botulinum toxin A (BTX-A; Dysport®) on use of oral rescue medication, bladder compliance, continence and quality of life in a randomized, placebo-controlled, double-blind study in patients with incontinence due to neurogenic detrusor overactivity. As this group of patients often have severe symptoms, oral tolterodine was allowed as rescue medication and the amount of tolterodine consumed was our primary endpoint. Material and methods. A total of 31 patients with urinary leakage due to spinal cord injury, myelomeningocele, trauma at birth, multiple sclerosis and myelitis of another cause were randomized to intravesical injections of either 500 U of BTX-A or placebo. Intake of tolterodine and episodes of urinary leakage were registered. Cystometry was performed after 6, 12 and 26 weeks and quality of life was assessed. Results. Patients in the BTX-A group had a significantly lower intake of tolterodine throughout the study compared to those in the placebo group (p=0.003). Cystometric capacity was significantly higher at 6 (p<0.001) and 12 weeks (p=0.026) and maximum detrusor pressure and frequency of urinary leakage were significantly (p<0.01) lower during follow-up in the BTX-A group compared to the placebo group. In addition, many quality-of-life parameters were significantly improved in the BTX-A group compared to the placebo group. Conclusions. Intravesical injection of 500 U of BTX-A in patients with neurogenic detrusor instability was shown to be an effective treatment which reduced use of oral medication, high detrusor pressure and frequency of urinary leakage during the overall study period of 26 weeks. Quality of life was also significantly improved.</description><identifier>ISSN: 0036-5599</identifier><identifier>EISSN: 1651-2065</identifier><identifier>DOI: 10.1080/00365590601068835</identifier><identifier>PMID: 17763227</identifier><identifier>CODEN: SJUNAS</identifier><language>eng</language><publisher>Basingstoke: Taylor & Francis</publisher><subject>Administration, Oral ; Benzhydryl Compounds - administration & dosage ; Biological and medical sciences ; Botulinum toxin A ; Botulinum Toxins, Type A - administration & dosage ; Botulinum Toxins, Type A - therapeutic use ; Cresols - administration & dosage ; detrusor overactivity ; Double-Blind Method ; Dysport ; Female ; Humans ; incontinence ; Male ; Medical sciences ; Muscarinic Antagonists - administration & dosage ; Nephrology. Urinary tract diseases ; neurogenic bladder ; Phenylpropanolamine - administration & dosage ; Quality of Life ; Tolterodine Tartrate ; Urinary Bladder, Overactive - drug therapy ; Urinary system involvement in other diseases. Miscellaneous ; Urinary tract. Prostate gland</subject><ispartof>Scandinavian journal of urology and nephrology, 2007-01, Vol.41 (4), p.335-340</ispartof><rights>2007 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2007</rights><rights>2007 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c372t-f3ed8a64fbfbf577a2b1b1c20734480ab2d5fce515661369cc69e2b905f654dd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/00365590601068835$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/00365590601068835$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>230,314,780,784,885,27923,27924,59646,59752,60435,60541</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19054213$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17763227$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:115798247$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Ehren, Ingrid</creatorcontrib><creatorcontrib>Volz, Daniela</creatorcontrib><creatorcontrib>Farrelly, Elisabeth</creatorcontrib><creatorcontrib>Berglund, Lena</creatorcontrib><creatorcontrib>Brundin, Lou</creatorcontrib><creatorcontrib>Hultling, Claes</creatorcontrib><creatorcontrib>Lafolie, Pierre</creatorcontrib><title>Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: A randomized, placebo-controlled, double-blind study</title><title>Scandinavian journal of urology and nephrology</title><addtitle>Scand J Urol Nephrol</addtitle><description>Objective. To evaluate the effect of a single injection of 500 U of botulinum toxin A (BTX-A; Dysport®) on use of oral rescue medication, bladder compliance, continence and quality of life in a randomized, placebo-controlled, double-blind study in patients with incontinence due to neurogenic detrusor overactivity. As this group of patients often have severe symptoms, oral tolterodine was allowed as rescue medication and the amount of tolterodine consumed was our primary endpoint. Material and methods. A total of 31 patients with urinary leakage due to spinal cord injury, myelomeningocele, trauma at birth, multiple sclerosis and myelitis of another cause were randomized to intravesical injections of either 500 U of BTX-A or placebo. Intake of tolterodine and episodes of urinary leakage were registered. Cystometry was performed after 6, 12 and 26 weeks and quality of life was assessed. Results. Patients in the BTX-A group had a significantly lower intake of tolterodine throughout the study compared to those in the placebo group (p=0.003). Cystometric capacity was significantly higher at 6 (p<0.001) and 12 weeks (p=0.026) and maximum detrusor pressure and frequency of urinary leakage were significantly (p<0.01) lower during follow-up in the BTX-A group compared to the placebo group. In addition, many quality-of-life parameters were significantly improved in the BTX-A group compared to the placebo group. Conclusions. Intravesical injection of 500 U of BTX-A in patients with neurogenic detrusor instability was shown to be an effective treatment which reduced use of oral medication, high detrusor pressure and frequency of urinary leakage during the overall study period of 26 weeks. Quality of life was also significantly improved.</description><subject>Administration, Oral</subject><subject>Benzhydryl Compounds - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Botulinum toxin A</subject><subject>Botulinum Toxins, Type A - administration & dosage</subject><subject>Botulinum Toxins, Type A - therapeutic use</subject><subject>Cresols - administration & dosage</subject><subject>detrusor overactivity</subject><subject>Double-Blind Method</subject><subject>Dysport</subject><subject>Female</subject><subject>Humans</subject><subject>incontinence</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Muscarinic Antagonists - administration & dosage</subject><subject>Nephrology. Urinary tract diseases</subject><subject>neurogenic bladder</subject><subject>Phenylpropanolamine - administration & dosage</subject><subject>Quality of Life</subject><subject>Tolterodine Tartrate</subject><subject>Urinary Bladder, Overactive - drug therapy</subject><subject>Urinary system involvement in other diseases. Miscellaneous</subject><subject>Urinary tract. Prostate gland</subject><issn>0036-5599</issn><issn>1651-2065</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kD1PwzAQhi0EoqXwA1iQF8aAP2InkVgqVD6kSiwwR45jgyGxi-209N_jqoUOCHk46-55Xp0OgHOMrjAq0TVClDNWIY4w4mVJ2QEYY85wRhBnh2C8mWcJqEbgJIR3hBDhmB-DES4KTgkpxqCfaW2kkGsobAtNvxAyQqdh4-LQGTv0MLovY-EUOgs_B9GZuN7MO6MVTP2FiEbZGODKxDdo1eDdq7JGwlZFPwTnoVsqn0LNMpmn4EiLLqizXZ2Al7vZ8-1DNn-6f7ydzjNJCxIzTVVbCp7rJj1WFII0uMGSoILmeYlEQ1qmpWKYcY4pr6TklSJNhZjmLG9bOgHZNjes1GJo6oU3vfDr2glT71of6adqxkuGeeLxlpfeheCV_jUwqjenrv-cOjkXWyel9ardG7vbJuByB4ggRae9sNKEPZfWzQmmibvZcsZq53uxcr5r6yjWnfM_Ev1_j28zqptg</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Ehren, Ingrid</creator><creator>Volz, Daniela</creator><creator>Farrelly, Elisabeth</creator><creator>Berglund, Lena</creator><creator>Brundin, Lou</creator><creator>Hultling, Claes</creator><creator>Lafolie, Pierre</creator><general>Taylor & Francis</general><general>Taylor and Francis</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>20070101</creationdate><title>Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity</title><author>Ehren, Ingrid ; Volz, Daniela ; Farrelly, Elisabeth ; Berglund, Lena ; Brundin, Lou ; Hultling, Claes ; Lafolie, Pierre</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-f3ed8a64fbfbf577a2b1b1c20734480ab2d5fce515661369cc69e2b905f654dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Administration, Oral</topic><topic>Benzhydryl Compounds - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Botulinum toxin A</topic><topic>Botulinum Toxins, Type A - administration & dosage</topic><topic>Botulinum Toxins, Type A - therapeutic use</topic><topic>Cresols - administration & dosage</topic><topic>detrusor overactivity</topic><topic>Double-Blind Method</topic><topic>Dysport</topic><topic>Female</topic><topic>Humans</topic><topic>incontinence</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Muscarinic Antagonists - administration & dosage</topic><topic>Nephrology. Urinary tract diseases</topic><topic>neurogenic bladder</topic><topic>Phenylpropanolamine - administration & dosage</topic><topic>Quality of Life</topic><topic>Tolterodine Tartrate</topic><topic>Urinary Bladder, Overactive - drug therapy</topic><topic>Urinary system involvement in other diseases. Miscellaneous</topic><topic>Urinary tract. Prostate gland</topic><toplevel>online_resources</toplevel><creatorcontrib>Ehren, Ingrid</creatorcontrib><creatorcontrib>Volz, Daniela</creatorcontrib><creatorcontrib>Farrelly, Elisabeth</creatorcontrib><creatorcontrib>Berglund, Lena</creatorcontrib><creatorcontrib>Brundin, Lou</creatorcontrib><creatorcontrib>Hultling, Claes</creatorcontrib><creatorcontrib>Lafolie, Pierre</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Scandinavian journal of urology and nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ehren, Ingrid</au><au>Volz, Daniela</au><au>Farrelly, Elisabeth</au><au>Berglund, Lena</au><au>Brundin, Lou</au><au>Hultling, Claes</au><au>Lafolie, Pierre</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: A randomized, placebo-controlled, double-blind study</atitle><jtitle>Scandinavian journal of urology and nephrology</jtitle><addtitle>Scand J Urol Nephrol</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>41</volume><issue>4</issue><spage>335</spage><epage>340</epage><pages>335-340</pages><issn>0036-5599</issn><eissn>1651-2065</eissn><coden>SJUNAS</coden><abstract>Objective. To evaluate the effect of a single injection of 500 U of botulinum toxin A (BTX-A; Dysport®) on use of oral rescue medication, bladder compliance, continence and quality of life in a randomized, placebo-controlled, double-blind study in patients with incontinence due to neurogenic detrusor overactivity. As this group of patients often have severe symptoms, oral tolterodine was allowed as rescue medication and the amount of tolterodine consumed was our primary endpoint. Material and methods. A total of 31 patients with urinary leakage due to spinal cord injury, myelomeningocele, trauma at birth, multiple sclerosis and myelitis of another cause were randomized to intravesical injections of either 500 U of BTX-A or placebo. Intake of tolterodine and episodes of urinary leakage were registered. Cystometry was performed after 6, 12 and 26 weeks and quality of life was assessed. Results. Patients in the BTX-A group had a significantly lower intake of tolterodine throughout the study compared to those in the placebo group (p=0.003). Cystometric capacity was significantly higher at 6 (p<0.001) and 12 weeks (p=0.026) and maximum detrusor pressure and frequency of urinary leakage were significantly (p<0.01) lower during follow-up in the BTX-A group compared to the placebo group. In addition, many quality-of-life parameters were significantly improved in the BTX-A group compared to the placebo group. Conclusions. Intravesical injection of 500 U of BTX-A in patients with neurogenic detrusor instability was shown to be an effective treatment which reduced use of oral medication, high detrusor pressure and frequency of urinary leakage during the overall study period of 26 weeks. Quality of life was also significantly improved.</abstract><cop>Basingstoke</cop><pub>Taylor & Francis</pub><pmid>17763227</pmid><doi>10.1080/00365590601068835</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0036-5599 |
| ispartof | Scandinavian journal of urology and nephrology, 2007-01, Vol.41 (4), p.335-340 |
| issn | 0036-5599 1651-2065 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_00365590601068835 |
| source | MEDLINE; Taylor & Francis:Master (3349 titles); Taylor & Francis Medical Library - CRKN |
| subjects | Administration, Oral Benzhydryl Compounds - administration & dosage Biological and medical sciences Botulinum toxin A Botulinum Toxins, Type A - administration & dosage Botulinum Toxins, Type A - therapeutic use Cresols - administration & dosage detrusor overactivity Double-Blind Method Dysport Female Humans incontinence Male Medical sciences Muscarinic Antagonists - administration & dosage Nephrology. Urinary tract diseases neurogenic bladder Phenylpropanolamine - administration & dosage Quality of Life Tolterodine Tartrate Urinary Bladder, Overactive - drug therapy Urinary system involvement in other diseases. Miscellaneous Urinary tract. Prostate gland |
| title | Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: A randomized, placebo-controlled, double-blind study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T20%3A01%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20impact%20of%20botulinum%20toxin%20A%20on%20quality%20of%20life%20in%20patients%20with%20neurogenic%20detrusor%20overactivity:%20A%20randomized,%20placebo-controlled,%20double-blind%20study&rft.jtitle=Scandinavian%20journal%20of%20urology%20and%20nephrology&rft.au=Ehren,%20Ingrid&rft.date=2007-01-01&rft.volume=41&rft.issue=4&rft.spage=335&rft.epage=340&rft.pages=335-340&rft.issn=0036-5599&rft.eissn=1651-2065&rft.coden=SJUNAS&rft_id=info:doi/10.1080/00365590601068835&rft_dat=%3Cpubmed_cross%3E17763227%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17763227&rfr_iscdi=true |